Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Relationship between thyroid stimulating hormone and thyroid stimulating immunoglobulin in Graves' hyperthyroidism.

Woeber KA.

J Endocrinol Invest. 2011 Mar;34(3):222-4. doi: 10.3275/7268. Epub 2010 Sep 17.

PMID:
20855936
3.

Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.

Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.

J Clin Endocrinol Metab. 1996 Sep;81(9):3283-8.

PMID:
8784084
4.

A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.

Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ.

J Clin Endocrinol Metab. 2010 May;95(5):2123-31. doi: 10.1210/jc.2009-2470. Epub 2010 Mar 17.

PMID:
20237164
6.

Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.

Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T.

N Engl J Med. 1991 Apr 4;324(14):947-53.

7.

Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.

Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K.

J Endocrinol Invest. 1997 Sep;20(8):452-61.

PMID:
9364248
8.

Diagnostic value of a chimeric TSH receptor (Mc4)-based bioassay for Graves' disease.

Lee JI, Jang HW, Kim SK, Choi JY, Kim JY, Hur KY, Kim JH, Min YK, Chung JH, Kim SW.

Korean J Intern Med. 2011 Jun;26(2):179-86. doi: 10.3904/kjim.2011.26.2.179. Epub 2011 Jun 1.

9.

Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.

Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF.

Clin Endocrinol (Oxf). 2000 Mar;52(3):267-71.

PMID:
10718823
10.

A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.

Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, Kuma K.

Clin Endocrinol (Oxf). 1995 Nov;43(5):551-6.

PMID:
8548939
11.
12.

Measurement of thyroid stimulating immunoglobulins using a novel thyroid stimulating hormone receptor-guanine nucleotide-binding protein, (GNAS) fusion bioassay.

Pierce M, Sandrock R, Gillespie G, Meikle AW.

Clin Exp Immunol. 2012 Nov;170(2):115-21. doi: 10.1111/j.1365-2249.2012.04648.x.

13.

Further evaluation of an immunoprecipitation assay for TSH-receptor autoantibodies in Graves' disease.

De Bruin TW, Braverman LE, Brown RS.

Metabolism. 1986 Dec;35(12):1101-5.

PMID:
2878349
14.

Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.

Ochi Y, Kajita Y, Hamazu M, Nagata A.

Horm Res. 2003;59(5):222-8.

PMID:
12714785
15.
16.
17.

Thyroidal response to an increase or decrease of endogenous TSH in patients with hyperthyroidism and its correlation with TSH binding inhibiting immunoglobulin.

Katakura M, Koizumi Y, Aizawa T, Takasu N, Yamada T, Yukimura Y, Nagata H.

Clin Exp Pharmacol Physiol. 1986 May;13(5):407-15.

PMID:
2874908
18.

[The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].

Chen W, Man N, Li YS, Shan ZY, Teng WP.

Zhonghua Nei Ke Za Zhi. 2006 Feb;45(2):95-9. Chinese.

PMID:
16624113
20.

Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease.

Tada H, Mizuta I, Takano T, Tatsumi KI, Izumi Y, Hidaka Y, Amino N.

Clin Endocrinol (Oxf). 2003 Apr;58(4):403-8.

PMID:
12641621

Supplemental Content

Support Center